Compare TSLX & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TSLX | NUVB |
|---|---|---|
| Founded | 2010 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.1B |
| IPO Year | 2011 | 2020 |
| Metric | TSLX | NUVB |
|---|---|---|
| Price | $18.06 | $5.57 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 10 |
| Target Price | ★ $19.77 | $13.10 |
| AVG Volume (30 Days) | 363.2K | ★ 4.0M |
| Earning Date | 11-03-2026 | 11-02-2026 |
| Dividend Yield | ★ 9.82% | N/A |
| EPS Growth | N/A | ★ 71.56 |
| EPS | ★ 0.15 | N/A |
| Revenue | N/A | ★ $62,902,000.00 |
| Revenue This Year | N/A | $212.89 |
| Revenue Next Year | $3.99 | $41.68 |
| P/E Ratio | $122.30 | ★ N/A |
| Revenue Growth | N/A | ★ 698.96 |
| 52 Week Low | $16.04 | $3.36 |
| 52 Week High | $23.19 | $9.75 |
| Indicator | TSLX | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 46.69 | 36.84 |
| Support Level | $17.20 | $5.28 |
| Resistance Level | $18.59 | $5.77 |
| Average True Range (ATR) | 0.33 | 0.24 |
| MACD | -0.00 | -0.04 |
| Stochastic Oscillator | 34.95 | 14.87 |
Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. The company partners with other companies across a variety of industries and provides creative solutions with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.